Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Statement of Comprehensive Income [Abstract]
Consolidated net loss	$ (14,881)	$ (15,487)
Other comprehensive loss:
Change in unrealized loss on available-for-sale investments, net of tax	(26)	(84)
Comprehensive loss	(14,907)	(15,571)
Comprehensive loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited	1	(4)
Comprehensive loss attributable to aTyr Pharma, Inc. common stockholders	$ (14,906)	$ (15,575)